Global Biosimilars Market 2016-2020

PART 01: Executive summary
• Highlights

PART 02: Scope of the report
• Market overview
• Top-vendor offerings
• Assumptions

PART 03: Market research methodology
• Research methodology
• Economic indicators

PART 04: Introduction
• Key market highlights
• Biosimilars: Overview
• Comparative analysis of biosimilars and generic small molecules
• Biosimilars market opportunities
• Challenges for new entrants
• Bio-betters

PART 05: Pipeline portfolio

PART 06: Market landscape
• Market overview
• Five forces analysis

PART 07: Market segmentation by application
• Global blood disorders biosimilars market
• Market overview
• Global oncology biosimilars market
• Global chronic and autoimmune diseases biosimilars market
• Global growth hormone deficiency biosimilars market
• Global infectious diseases biosimilars market
• Others

PART 08: Market segmentation by end-user
• Hospitals
• Retail pharmacies

PART 09: Geographical segmentation
• Global biosimilars market by geographical segmentation 2015-2020
• Biosimilars market in EMEA
• Biosimilars market in APAC
• Biosimilars market in Americas

PART 10: Market drivers
• Rise in number of patent expiries
• Need for cost-effective treatment
• Reimbursement benefits for biosimilars
• Favorable government regulations
• Promising pipeline

PART 11: Impact of drivers

PART 12: Market challenges
• Physicians reluctance to prescribe biosimilars
• Multiple manufacturing complexities
• Risks related to drug failure
• Limited availability of biosimilar products
• Difficulties in patient recruitment for conducting clinical trials

PART 13: Impact of drivers and challenges

PART 14: Market trends
• Emergence of biosimilars
• Outsourcing of biosimilar manufacturing activities
• Need for high investment in R&D
• High growth in the emerging markets
• Rising number of strategic collaborations

PART 15: Vendor landscape
• Competitive scenario
• Sandoz
• Hospira
• Teva Pharmaceuticals
• STADA
• Biocon
• Celltrion
• Dr. Reddy's
• Other prominent vendors

PART 16: Appendix
• List of abbreviations

PART 17: Explore Technavio

List of Exhibits
Exhibit 01: Product offerings
Exhibit 02: Global biosimilar market snapshot
Exhibit 03: Key buying criteria for biosimilars 2015
Exhibit 04: Major timelines in global biosimilars market 2014-2020
Exhibit 05: Impact of key customer segments on market 2015
Exhibit 06: Definition of biosimilars in different regions
Exhibit 07: Comparison between biosimilars and generic small molecules
Exhibit 08: Factors affecting biologics and biosimilars market
Exhibit 09: Impact of biosimilars cost savings on various sectors
Exhibit 10: Factors affecting success of biosimilars
Exhibit 11: Biosimilars industry: Point-of-view
Exhibit 12: Factors influencing uptake of biosimilars
Exhibit 13: Global biosimilars market: Strategic factors for new market entrants
Exhibit 14: Challenges for new entrants
Exhibit 15: Bio-betters and its impact on market
Exhibit 16: Global biosimilars market: Pipeline snapshot 2015
Exhibit 17: Pipeline portfolio: Global biosimilars market 2015
Exhibit 18: Number of approved biosimilars in regulated and semi-regulated markets
Exhibit 19: Patent expirations of major biologics from 2000-2030
Exhibit 20: Global biosimilars market snapshot: Developed and emerging markets 2015
Exhibit 21: Patient assistance programs by vendors
Exhibit 22: Global biosimilars market 2015-2020 ($ billions)
Exhibit 23: Global spending for biosimilars 2015-2020 ($ billions)
Exhibit 24: Global biosimilars market: Key metrics analysis snapshot
Exhibit 25: Current and future trends in global biosimilars market
Exhibit 26: Impact of drivers and challenges on global biosimilars market
Exhibit 27: Five forces analysis
Exhibit 28: Global biosimilars market: Segmentation by application (2015-2020)
Exhibit 29: Applications of biosimilars and its impact on growth of market
Exhibit 30: Global biosimilars market: Segmentation by application 2015
Exhibit 31: Global biosimilars market segmentation: Growth cycle analysis
Exhibit 32: Global blood disorders market biosimilar 2015-2020 ($ billions)
Exhibit 33: Opportunity analysis of global blood disorders biosimilar market by type of application
Exhibit 34: Global oncology biosimilar market 2015-2020 ($ billions)
Exhibit 35: Opportunity analysis of global oncology biosimilar market by type of application
Exhibit 36: Population aged 60 years and over (millions)
Exhibit 37: Global chronic and autoimmune diseases biosimilars market 2015-2020 ($ millions)
Exhibit 38: Opportunity analysis of chronic and autoimmune diseases biosimilars market by application
Exhibit 39: Global growth hormone deficiency biosimilars market 2015-2020 ($ millions)
Exhibit 40: Opportunity analysis of global growth hormone deficiency biosimilars market
Exhibit 41: Global infectious diseases biosimilars market 2015-2020 ($ millions)
Exhibit 42: Opportunity analysis of infectious diseases biosimilars market by application
Exhibit 43: Global biosimilars market segmentation by application 2015
Exhibit 44: Biosimilars market segmentation by end-user 2015
Exhibit 45: Global biosimilars market: Geography outlook (2015-2020)
Exhibit 46: Global biosimilars market: Geography outlook 2015
Exhibit 47: Revenue/growth outlook in different countries/regions 2015
Exhibit 48: Biosimilar market landscape: Country analysis
Exhibit 49: Market penetration of originators and biosimilars in different regions
Exhibit 50: Biosimilars market in EMEA 2015-2020 ($ billions)
Exhibit 51: Biosimilars market in EMEA by region 2015
Exhibit 52: Guidelines for biosimilars in EU
Exhibit 53: Timeline of biosimilars in Europe
Exhibit 54: Geographical segmentation in Europe 2015
Exhibit 55: Patent expirations of major biologics in Europe
Exhibit 56: Key leading countries in EMEA 2015
Exhibit 57: Biosimilars market in Europe 2015-2020 ($ billions)
Exhibit 58: Europe biosimilars market: Opportunity analysis
Exhibit 59: Approved marketed products in Europe
Exhibit 60: Key stake holders in EU biosimilars market
Exhibit 61: PEST analysis: Biosimilars market in Europe 2015
Exhibit 62: Biosimilars market in Germany 2015-2020 ($ millions)
Exhibit 63: Biosimilars market in UK 2015-2020 ($ millions)
Exhibit 64: Biosimilars market in France 2015-2020 ($ millions)
Exhibit 65: Biosimilars market in Italy 2015-2020 ($ millions)
Exhibit 66: Biosimilars market in Spain 2015-2020 ($ millions)
Exhibit 67: Biosimilars market in APAC 2015-2020 ($ billions)
Exhibit 68: Biosimilars market in APAC by country 2015
Exhibit 69: Key leading countries in APAC 2015
Exhibit 70: Biosimilars market in China 2015-2020 ($ millions)
Exhibit 71: China biosimilars market: Opportunity analysis
Exhibit 72: PEST analysis: Biosimilars market in China
Exhibit 73: Timeline for development of biosimilars in India
Exhibit 74: Challenges and strategies in developing biosimilars in India
Exhibit 75: Biosimilars market in India 2015-2020 ($ millions)
Exhibit 76: India biosimilars market: Opportunity analysis
Exhibit 77: Approved biosimilars in India
Exhibit 78: PEST analysis: Biosimilars market in India 2015
Exhibit 79: Review process for biosimilars in Japan
Exhibit 80: Biosimilars approved by PMDA in Japan
Exhibit 81: Biosimilars market in Japan 2015-2020 ($ millions)
Exhibit 82: Biosimilars market in Japan: Opportunity analysis
Exhibit 83: PEST analysis: Biosimilars market in Japan 2015
Exhibit 84: Biosimilars market in Americas 2015-2020 ($ billions)
Exhibit 85: Approvals of biologicals versus biosimilars via public health service act (PHSA)
Exhibit 86: Timeline of biosimilar regulations in US
Exhibit 87: Approval process for biosimilars in US
Exhibit 88: Benefits of biosimilars to US healthcare system
Exhibit 89: Patent expirations of major biologics in US
Exhibit 90: Biosimilars market in US 2015-2020 ($ million)
Exhibit 91: Biosimilars market in US: Opportunity analysis
Exhibit 92: Role of stakeholders in creating awareness in US
Exhibit 93: PEST analysis: Biosimilars market in US 2015
Exhibit 94: Global biosimilars market: Key leading countries (2015)8
Exhibit 95: Patent analysis of biologicals in US
Exhibit 96: Patent analysis of biologicals in Europe
Exhibit 97: Impact of drivers
Exhibit 98: Key reasons as to why physicians are reluctant to prescribe biosimilar6
Exhibit 99: Impact of drivers and challenges
Exhibit 100: Global biosimilars market: Impact assessment of key trends
Exhibit 101: Competitive assessment of vendors
Exhibit 102: Key vendors: Geographical presence 2015
Exhibit 103: Mergers, acquisitions and
PARTnership assessment of major vendors in global biosimilars market
Exhibit 104: Sandoz: YoY revenue and growth rate of biosimilars 2014-2015 ($ millions)
Exhibit 105: Sandoz: Metrics analysis
Exhibit 106: Hospira: Metrics analysis4
Exhibit 107: Teva Pharmaceuticals: Metrics analysis6
Exhibit 108: STADA: Metrics analysis
Exhibit 109: Biocon: Metrics analysis
Exhibit 110: Celltrion: Metrics analysis
Exhibit 111: Dr. Reddy's: Metrics analysis

Menu 2

Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium doloremque laudantium, totam rem aperiam.

Menu 3

Eaque ipsa quae ab illo inventore veritatis et quasi architecto beatae vitae dicta sunt explicabo.